PT3592355T - Kx2-391/kx-01 para utilização no tratamento da queratose actínica - Google Patents

Kx2-391/kx-01 para utilização no tratamento da queratose actínica

Info

Publication number
PT3592355T
PT3592355T PT187649801T PT18764980T PT3592355T PT 3592355 T PT3592355 T PT 3592355T PT 187649801 T PT187649801 T PT 187649801T PT 18764980 T PT18764980 T PT 18764980T PT 3592355 T PT3592355 T PT 3592355T
Authority
PT
Portugal
Prior art keywords
treatment
actinic keratosis
keratosis
actinic
Prior art date
Application number
PT187649801T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Atnx Spv Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63446658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3592355(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnx Spv Llc filed Critical Atnx Spv Llc
Publication of PT3592355T publication Critical patent/PT3592355T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT187649801T 2017-03-10 2018-03-12 Kx2-391/kx-01 para utilização no tratamento da queratose actínica PT3592355T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762469889P 2017-03-10 2017-03-10

Publications (1)

Publication Number Publication Date
PT3592355T true PT3592355T (pt) 2026-02-03

Family

ID=63446658

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187649801T PT3592355T (pt) 2017-03-10 2018-03-12 Kx2-391/kx-01 para utilização no tratamento da queratose actínica

Country Status (23)

Country Link
US (3) US10617693B2 (https=)
EP (2) EP3592355B1 (https=)
JP (3) JP7502863B2 (https=)
KR (2) KR20240090837A (https=)
CN (1) CN110891575A (https=)
AU (2) AU2018231144B2 (https=)
BR (1) BR112019018687A2 (https=)
CA (1) CA3055938A1 (https=)
DK (1) DK3592355T3 (https=)
ES (1) ES3060528T3 (https=)
FI (1) FI3592355T3 (https=)
HR (1) HRP20260155T1 (https=)
IL (1) IL269182B2 (https=)
LT (1) LT3592355T (https=)
MX (2) MX387658B (https=)
NZ (1) NZ757105A (https=)
PL (1) PL3592355T3 (https=)
PT (1) PT3592355T (https=)
RS (1) RS67713B1 (https=)
SI (1) SI3592355T1 (https=)
TW (1) TWI841523B (https=)
WO (1) WO2018165647A1 (https=)
ZA (1) ZA202100106B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
FI3592355T3 (fi) * 2017-03-10 2026-02-13 Atnx Spv Llc KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa
IL326637A (en) 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
CN117599189A (zh) * 2018-03-07 2024-02-27 慧源Spv公司 用于治疗过度增殖性皮肤障碍的组合物和方法
JP7296945B2 (ja) * 2018-03-28 2023-06-23 テルモ株式会社 医療デバイス
WO2020247706A1 (en) * 2019-06-05 2020-12-10 Athenex, Inc. Methods of treating and/or preventing psoriasis
JP2024506240A (ja) * 2021-01-21 2024-02-13 サーナオミクス インコーポレイテッド 皮膚がんの治療のための組成物および方法
WO2025077886A1 (zh) * 2023-10-13 2025-04-17 恩康药业科技(广州)有限公司 治疗和/或预防日光性角化病的化合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
ES2382068T3 (es) 2004-12-28 2012-06-05 Kinex Pharmaceuticals, Llc Composiciones y métodos para tratar trastornos de proliferación celular
JP5564251B2 (ja) 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ, エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
WO2008030892A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
WO2008144045A1 (en) 2007-05-17 2008-11-27 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
SI2378876T1 (sl) * 2008-12-19 2019-05-31 Medicis Pharmaceutical Corporation Formulacije z nižjo dozirno jakostjo imikvimoda in kratki odmerni režimi za zdravljenje aktinične keratoze
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
US8741857B1 (en) * 2012-01-30 2014-06-03 Lawrence Moy Treatments for actinic keratoses
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はahi1の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
FI3592355T3 (fi) * 2017-03-10 2026-02-13 Atnx Spv Llc KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa

Also Published As

Publication number Publication date
CN110891575A (zh) 2020-03-17
KR20190141661A (ko) 2019-12-24
DK3592355T3 (da) 2026-02-16
IL269182B2 (en) 2023-11-01
MX2021013354A (es) 2021-11-18
US20200197405A1 (en) 2020-06-25
KR20240090837A (ko) 2024-06-21
AU2018231144B2 (en) 2023-12-21
JP2023015269A (ja) 2023-01-31
AU2024201828A1 (en) 2024-05-02
LT3592355T (lt) 2026-02-25
JP2025029010A (ja) 2025-03-05
US20180256589A1 (en) 2018-09-13
JP2020510042A (ja) 2020-04-02
HRP20260155T1 (hr) 2026-03-27
RU2019131757A3 (https=) 2021-05-31
TWI841523B (zh) 2024-05-11
EP4659740A3 (en) 2026-02-18
EP3592355A1 (en) 2020-01-15
US11497750B2 (en) 2022-11-15
TW201842913A (zh) 2018-12-16
US10617693B2 (en) 2020-04-14
EP3592355B1 (en) 2025-12-10
NZ757105A (en) 2026-02-27
RS67713B1 (sr) 2026-02-27
AU2024201828B2 (en) 2026-02-19
US20230172942A1 (en) 2023-06-08
SI3592355T1 (sl) 2026-04-30
BR112019018687A2 (pt) 2020-04-07
EP4659740A2 (en) 2025-12-10
WO2018165647A1 (en) 2018-09-13
MX2019010707A (es) 2020-01-15
FI3592355T3 (fi) 2026-02-13
AU2018231144A1 (en) 2019-10-03
ZA202100106B (en) 2022-08-31
IL269182A (en) 2019-11-28
EP3592355A4 (en) 2021-01-06
RU2019131757A (ru) 2021-04-12
MX387658B (es) 2025-03-18
JP7502863B2 (ja) 2024-06-19
IL269182B1 (en) 2023-07-01
PL3592355T3 (pl) 2026-04-07
CA3055938A1 (en) 2018-09-13
ES3060528T3 (en) 2026-03-26

Similar Documents

Publication Publication Date Title
CY2025027I2 (el) Ελαφιμπρανορη για χρηση στην αντιμετωπιση πρωτοπαθους χολικης χολαγγειτιδας
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
IL281793A (en) Use of cannabinoids in the treatment of epilepsy
IL279752A (en) Polycyclic compounds and use thereof in the treatment of immune disorders
PT3661514T (pt) Mavacamten para utilização no tratamento da cardiomiopatia hipertrófica
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
PT3592355T (pt) Kx2-391/kx-01 para utilização no tratamento da queratose actínica
PL3157511T3 (pl) Zastosowanie kannabinoidów w leczeniu padaczki
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
PT3562486T (pt) Uso de dexmedetomidina sublingual para o tratamento da agitação
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
IL251530B (en) Use of cannabinoids in the treatment of degenerative skeletal muscle diseases
PL3429571T3 (pl) Kombinacje inhibitorów lsd1 do zastosowania w leczeniu chorób nowotworowych
BR112016026378A2 (pt) formulações e métodos para tratamento com queratina
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
PL3432872T3 (pl) Eflornityna do zastosowania w leczeniu nawracającego/opornego na leczenie temozolomidem gwiaździaka anaplastycznego
IL268728A (en) Formulations of cannabinoids for the treatment of acne
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
HUE058645T2 (hu) Gyógyszer köszvény kezelésében való felhasználásra
PT3405197T (pt) Utilização de delgocitinib para o tratamento de eczema crónico das mãos
PT3322438T (pt) Inibidores de il-8 para utilização no tratamento de determinados distúrbios urológicos
HUE065202T2 (hu) Készítmény bélelváltozások kezelésében való felhasználásra
PT3383381T (pt) Composto para uso na prevenção e tratamento de doenças neurodegenerativas